Equities research analysts at BTIG Research initiated coverage on shares of AnaptysBio (NASDAQ:ANAB – Get Free Report) in a report released on Monday, Benzinga reports. The brokerage set a “buy” rating and a $55.00 price target on the biotechnology company’s stock. BTIG Research’s price target suggests a potential upside of 112.60% from the stock’s previous close.
A number of other equities research analysts have also recently commented on ANAB. UBS Group decreased their price objective on AnaptysBio from $28.00 to $21.00 and set a “neutral” rating for the company in a research note on Thursday, November 2nd. Stifel Nicolaus initiated coverage on AnaptysBio in a research note on Wednesday, February 21st. They set a “buy” rating and a $50.00 price objective for the company. Wedbush reaffirmed a “neutral” rating and set a $20.00 price objective on shares of AnaptysBio in a research note on Wednesday, November 29th. StockNews.com cut AnaptysBio from a “hold” rating to a “sell” rating in a research note on Friday, November 3rd. Finally, Piper Sandler initiated coverage on AnaptysBio in a research note on Friday, February 16th. They issued an “overweight” rating and a $80.00 target price for the company. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, AnaptysBio currently has a consensus rating of “Hold” and a consensus price target of $43.00.
AnaptysBio Stock Performance
NASDAQ ANAB opened at $25.87 on Monday. AnaptysBio has a 52 week low of $13.36 and a 52 week high of $26.12. The stock has a fifty day moving average of $22.79 and a 200-day moving average of $19.47. The stock has a market capitalization of $687.62 million, a P/E ratio of -4.77 and a beta of -0.30.
Insiders Place Their Bets
In other news, CFO Dennis Mulroy sold 2,180 shares of the company’s stock in a transaction that occurred on Monday, January 8th. The stock was sold at an average price of $21.81, for a total value of $47,545.80. Following the transaction, the chief financial officer now owns 4,029 shares of the company’s stock, valued at $87,872.49. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Paul F. Lizzul sold 2,554 shares of the stock in a transaction that occurred on Monday, January 8th. The stock was sold at an average price of $21.81, for a total transaction of $55,702.74. Following the sale, the insider now owns 10,118 shares of the company’s stock, valued at $220,673.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Dennis Mulroy sold 2,180 shares of the stock in a transaction that occurred on Monday, January 8th. The stock was sold at an average price of $21.81, for a total value of $47,545.80. Following the sale, the chief financial officer now directly owns 4,029 shares in the company, valued at approximately $87,872.49. The disclosure for this sale can be found here. Insiders have sold a total of 19,665 shares of company stock valued at $450,422 over the last 90 days. 35.50% of the stock is currently owned by insiders.
Institutional Investors Weigh In On AnaptysBio
A number of large investors have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD lifted its stake in AnaptysBio by 2.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 231,754 shares of the biotechnology company’s stock worth $4,965,000 after purchasing an additional 5,472 shares during the last quarter. Palo Alto Investors LP lifted its stake in AnaptysBio by 59.3% during the fourth quarter. Palo Alto Investors LP now owns 686,882 shares of the biotechnology company’s stock worth $14,713,000 after purchasing an additional 255,658 shares during the last quarter. Octagon Capital Advisors LP bought a new stake in AnaptysBio during the fourth quarter worth $2,570,000. Great Point Partners LLC lifted its stake in AnaptysBio by 9.2% during the fourth quarter. Great Point Partners LLC now owns 976,981 shares of the biotechnology company’s stock worth $20,927,000 after purchasing an additional 82,648 shares during the last quarter. Finally, Brevan Howard Capital Management LP bought a new stake in AnaptysBio during the fourth quarter worth $207,000.
About AnaptysBio
AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 trial for the treatment of generalized pustular psoriasis; Rosnilimab, an anti-PD-1 agonist antibody program designed to suppress T-cell driven inflammatory diseases by augmenting signaling through PD-1 or targeted depletion of PD-1+ T cells; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.